Bellicum Pharmaceuticals, Inc. (BLCM)
(Delayed Data from NSDQ)
$3.15 USD
+0.13 (4.30%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.15 USD
+0.13 (4.30%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
by Zacks Equity Research
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Bellicum Pharmaceuticals (BLCM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
by Zacks Equity Research
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
Bet on Rising P/E With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
by Zacks Equity Research
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.
Cronos Group (CRON) Catches Eye: Stock Jumps 9.3%
by Zacks Equity Research
Cronos Group (CRON) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rising P/E: An Ignored Trick to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
Translate Bio Up on Vaccine Agreement Expansion With Sanofi
by Zacks Equity Research
Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval
by Zacks Equity Research
FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.
Top Ranked Momentum Stocks to Buy for June 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 1st
All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for September 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 23rd
Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.